The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAligos Therapeutics (Nasdaq: ALGS) has announced an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium. The partnership focuses on treating chronic hepatitis B virus (HBV) infections across the Greater China region, including Mainland China, Taiwan, Hong Kong, and Macau. By leveraging Amoytop's regional expertise, Aligos aims to accelerate the clinical development and commercial reach of its HBV therapeutic in a high-prevalence market. While specific financial terms were not fully disclosed, the deal is expected to generate milestone payments and royalties for Aligos. This strategic move highlights the potential of Aligos' drug pipeline in addressing significant global health challenges. Analysts view this collaboration as a bullish development for the company's expansion strategy in Asia.